Industry

High Throughput Process Development Strategic Business Report 2025: Market to Reach $24.6 Billion by 2030 – Surge in Demand for Personalized Medicine Strengthens Opportunities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “High Throughput Process Development – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for High Throughput Process Development was valued at US$15.3 Billion in 2024 and is projected to reach US$24.6 Billion by 2030, growing at a CAGR of 8.3% from 2024 to 2030. This comprehensive report … [Read more…]

FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® … [Read more…]

MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease

Oral presentation highlights updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with Xervyteg® Independent dataset from EAP reinforces the findings from the pivotal ARES trial and has also been included in the EMA Marketing Authorization Application submitted on June 2nd, 2025 EAP for Xervyteg® in aGvHD is … [Read more…]

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

Preclinical data from IPH6501, Innate’s proprietary ANKET® targeting CD20, demonstrating potent antitumor activity in vitro on patient-derived samples from Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL), will be presented Preclinical in vivo models support enhanced antitumor efficacy for the combination of IPH6501 with R-CHOP, the standard of care in untreated DLBCL and FL … [Read more…]

SINOVAC’s Board of Directors Issues a Letter to Shareholders Outlining Clear Pathway to Restore Fairness and Deliver Value to All Shareholders

Intends to file definitive proxy materials in the coming days BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it intends to file its definitive proxy materials in the coming days with the Securities and Exchange Commission (SEC) for the Special Meeting of … [Read more…]

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free … [Read more…]

HSS Research at EULAR 2025 Congress Shows Routine Test Could Enable Faster, More-Effective Personalized Rheumatoid Arthritis Treatment

BARCELONA, Spain–(BUSINESS WIRE)–Hospital for Special Surgery (HSS) presented new findings at the European Alliance of Associations for Rheumatology (EULAR) Annual Meeting that could help pave the way for more personalized treatment for people with rheumatoid arthritis (RA) by analyzing the cellular composition of synovial fluid inside their joints. RA is a chronic disease characterized by … [Read more…]

EY US Announces Nabiha Saklayen of Cellino as an Entrepreneur Of The Year® 2025 New England Award Winner

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future BOSTON–(BUSINESS WIRE)–#EY–Ernst & Young LLP (EY US) has named Nabiha Saklayen, Ph.D., CEO and Co-Founder of Cellino, a winner of the Entrepreneur Of The Year® 2025 New England Award. Now celebrating its 40th year, Entrepreneur Of The Year is one of the most … [Read more…]

Presidio Medical™ Receives IDE Approval for Ultra Low Frequency (ULF™) Neuromodulation Clinical Study and Appoints Dimas Jiménez as Chief Financial Officer

FDA Investigational Device Exemption (IDE) Approval enables Presidio’s ULF platform technology to be tested in a pivotal clinical trial in the United States, representing a significant step in bringing this transformational technology to patients who suffer from chronic nociceptive low back pain. SAN MATEO, Calif.–(BUSINESS WIRE)–Presidio Medical, Inc., a global clinical-stage medical device company developing … [Read more…]

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Innovative Agents Highlight Growth of Targeted Protein Degradation Platform and BMS’ Leadership in Innovative Cancer Therapies PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new data from its targeted protein degradation platform during the 2025 European Hematology Association (EHA) Annual Congress being held from June 12-15 in Milan, Italy. Presentations … [Read more…]